CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out what effects (the good and bad) the
combination treatment of metformin and CPI-613 has in treating participants with acute
myeloid leukemia or granulocytic sarcoma that has either returned after treatment or did not
respond to treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborators:
Cornerstone Pharmaceuticals National Cancer Institute (NCI)